Clinical Trial Update: Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial comparing MTBVAC to BCG in newborns with a safety arm in adults to evaluate safety and immunogenicity for tuberculosis vaccination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• BCG vaccine (Bacillus Calmette-Guérin)
• MTBVAC

Snippet

Sponsor: Biofabri, S.L | Conditions: Tuberculosis | Phase 1, Phase 2 | Status: COMPLETED